1Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146(suppl 61):1-6.
2Thompson JF, Scolyer RA, Keffrd RF. Cutaneous Melanoma. Lancet 2005;365:687-701.
3De Vries E, Bray FI, Coebergh JWW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997:rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107:119-126.
4Bosetti C, La Vecchia C, Naldi L, Lucchini F, Negri E, Levi F. Mortality from Cutaneous malignant melanoma in Europe. Has The epidemic levelled off ? Mel Res 2004;14(4):301-309.
5Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
6Subungueal melanoma: a particularly invasive ‘’onychomycosis’’.
De Giorgi V, Sestini S, Massi D, Panelos J, Papi F, Dini M, Lotti T.
J Am Geriatr Soc. 2007 Dec;55(12):2094-6. No abstract available.
7Carli P, De Giorgi V, Giannotti B, et al. Relationship between cause of referral and diagnostic outcome in pigmented lesion clinics aimed to melanoma screening: a multicenter survey of the Italian Multidisciplinary group on Melanoma (GIPMe). Melanoma Research 2003; 13: 207-211.
8Stolz W, Riemann A, Cognetta AB, et al. ABCD rule of dermatoscopy: a new practical method for early recognition of melanoma. Eur J Dermatol 1994; 4: 521-527.
9Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003;200:314-319.
10Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm KF, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
11Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220(6);759-767.
12Sentinel lymph nodes in melanoma patients: evaluating the evidence
De Giorgi V, Leporatti G, Massi D, Lo Russo G, Sestini S, Papi F, Dini M, Lotti T.
Oncology. 2006;71(5-6):460-2. Epub 2007 Sep 14.
13Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-983.
14Outcome of patients with melanoma and histologically negative sentinel lymph nodes: one institution’s experience.
De Giorgi V, Leporatti G, Massi D, Lo Russo G, Sestini S, Dini M, Lotti T.
Oncology. 2007;73(5-6):401-6. Epub 2008 Jun 2.
15Estourgie SH, Nieweg OE, Valdes Olmos RA, Hoefnagel CA, Kroon BB. Ann Surg Oncol 2003;10(6):681-688.
16Nowecki ZI, Rutkowski P, Guttmejer AN, Ruka W. Sentinel lymph node biopsy in melanoma patients with clinical negative regional lymph nodes – one snstitution’s experience. Mel Res 2003;13(1):35-43.
17Borgognoni L, Urso C, Vaggelli L, Brandani P, Gerlini G, Reali UM. Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation. Melanoma Res 2004; 14:311-319.
18Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming JD, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
19Carlson GW, Murray DR, Hestley A, Staley CA, Lyles RH, Cohen C. Sentinel lymph node mapping for thick (³4mm) melanoma: should we be doing it ? Ann Surg Oncol 2003;10(4):408-415.
20Cole BF, Gelber RD, Kirkwood JM, et al Quality-of-life-adjusted Survival analysis of Interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 14:2666-2673, 1996
21Ravaud A, Bedane C, Geoffrois L, Lesimple T, Delaunay M. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer 1999; 80: 1767-1769.
22Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002 Sep 1;20(17):3703-18.
23Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106(7):1431-42.
Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164-168.
24Luikart SD, Kennealey GT, Kirkwood JM. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol 1984; 2: 164-168.
25Dorval T, Negrier S, Chevreau C, Avril MF, Baume D, Cupissol D, et al. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 1999; 85: 1060-1066.
26Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968-975.
27Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004;363(31):345-351.
28Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M, Schlagenhauff B, Meier F, Schittek B, Blaheta HJ, Blum A, Rassner G. Prospective evaluation of a folow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003;21(3):520-529.
29Buzaid CA, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995;13(8):2104-2108.
|
